A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：1
|
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCES 01.12
引用
收藏
页码：S1735 / S1735
页数：1
相关论文
共 50 条
  • [1] Phase II study of fruquintinib plus gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations
    Lu, S.
    Zhou, J.
    Niu, X.
    Chen, Y.
    Su, W.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
    Saltos, Andreas N.
    Creelan, Ben C.
    Tanvetyanon, Tawee
    Chiappori, Alberto A.
    Antonia, Scott J.
    Shafique, Michael R.
    Ugrenovic-Petrovic, Milijana
    Sansil, Samer
    Neuger, Anthony
    Ozakinci, Hilal
    Boyle, Theresa A.
    Kim, Jongphil
    Haura, Eric B.
    Gray, Jhanelle E.
    LUNG CANCER, 2023, 183
  • [3] Systemic Therapy for Oligoprogression in Patients with Metastatic NSCLC Harboring Activating EGFR Mutations
    Rossi, Antonio
    Galetta, Domenico
    CANCERS, 2022, 14 (03)
  • [4] A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
    Suzuki, K.
    Imai, H.
    Kaira, K.
    Anzai, M.
    Tsuda, T.
    Ishizuka, T.
    Kuwako, T.
    Naruse, I.
    Nemoto, K.
    Uchino, J.
    Morozumi, N.
    Ishihara, S.
    Minato, K.
    Hisada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S498 - S498
  • [5] Phase I/II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations
    Shimizu, Toshio
    Nokihara, Hiroshi
    Murakami, Haruyasu
    Seto, Takashi
    Nishio, Makoto
    Takeda, Koji
    Inoue, Akira
    Kiura, Katsuyuki
    Azuma, Koichi
    Keating, Anne
    Krivoshik, Andrew
    Uegaki, Koichi
    Takeda, Kentaro
    Komatsu, Kanji
    Morita, Satoshi
    Fukuoka, Masahiro
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2015, 26 : 82 - 82
  • [6] Efficacy of the combination cisplatin-vinorelbin followed by docetaxel in untreated unresectable patients with NSCLC (stage IIIB-IV). A phase II study
    Piantedosi, F. V.
    Bianco, A.
    Caputo, F.
    Pisanti, C.
    Pontillo, A.
    Curcio, C.
    Crispino, C.
    Giuliarini, G.
    Hengeller, M.
    Marsico, S. A.
    Chianca, P.
    ANNALS OF ONCOLOGY, 2005, 16 : 23 - 23
  • [7] A prospective study to correlate EGFR mutations with gefitinib response in early stage NSCLC
    Rizvi, N
    Pao, W
    Miller, V
    Rusch, V
    Heelan, R
    Ladanyi, M
    Ginex, P
    Tyson, L
    Zakowski, M
    Kris, M
    LUNG CANCER, 2005, 49 : S43 - S43
  • [8] A PHASE II STUDY OF ERLOTINIB AS FIRST-LINE TREATMENT IN JAPANESE ADVANCED NSCLC PATIENTS HARBORING EGFR MUTATIONS
    Horiike, A.
    Nishio, M.
    Goto, K.
    Yamamoto, N.
    Chikamori, K.
    Maemondo, M.
    Hida, T.
    Katakami, N.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 413 - 413
  • [9] Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
    Passaro, A.
    De Marinis, F.
    Tu, H.
    Laktionov, K. K.
    Feng, J.
    Poltoratskiy, A.
    Zhao, J.
    Tan, E-H.
    Gottfried, M.
    Lee, V.
    Kowalski, D.
    Yang, C-T.
    Srinivasa, B.
    Clementi, L.
    Tang, W.
    Huang, D. C-L.
    Cseh, A.
    Park, K.
    Zhou, C.
    Wu, Y-L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] PHASE II TRIAL OF FIRSTLINE TRIAL OF CBDCA PLUS S1 PLUS GEFITINIB FOR PATIENTS WITH ADVANCED NSCLC PATIENTS HARBORING ACTIVATING MUTATION OF THE EGFR GENE
    Tsuji, T.
    Tamiya, M.
    Tamiya, A.
    Omachi, N.
    Minomo, S.
    Asami, K.
    Okishio, K.
    Kawaguchi, T.
    Shiroyama, T.
    Morishita, N.
    Suzuki, H.
    Okamoto, N.
    Kobayashi, S.
    Hirashima, T.
    Atagi, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 23 - 23
12345